Background: Molnupiravir is approved for the treatment of adult patients with mild to
moderate COVID-19. The main goal of the treatment is to reduce hospitalization and …

Background Molnupiravir is an oral prodrug of β-d-N4-hydroxycytidine, active against SARS-
CoV-2 in vitro and in animal models. We report data from the phase 2 component of MOVe …

Purpose Molnupiravir is an oral antiviral agent authorized for emergency use to treat mild to
moderate cases of coronavirus disease 2019 (COVID-19) in adults at high risk for …

Real-life experience of molnupiravir treatment is lacking, especially in people hospitalized
for underlying diseases not related to COVID-19. We conducted a retrospective analysis …

Background Safe and effective oral treatments are needed to improve clinical outcomes for
nonhospitalized patients with Covid-19. Molnupiravir is an orally administered, small …

Background The effects of molnupiravir in treating patients with non-severe COVID-19
remain uncertain. Objectives To evaluate the efficacy and safety of molnupiravir in adult …

Background Molnupiravir (MOL) is an oral antiviral medication that has recently been treated
for COVID-19. Objectively We perform a prospective and observational study to elucidate the …

The efficacy of molnupiravir in treating patients with coronavirus disease 2019 (COVID‐19)
has been inconsistent across randomized controlled trials (RCTs). Thus, this meta‐analysis …

Background Molnupiravir has been considered a promising candidate for COVID-19. Its
efficacy and safety in non-severe COVID-19 patients and the differences between patients …

Background The majority of available data on molnupiravir come from an unvaccinated
COVID-19 population. Therefore, we conducted this meta-analysis to integrate evidence …